Jakob Dupont's most recent trade in Bolt Biotherapeutics Inc was a trade of 1,100 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 27, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bolt Biotherapeutics Inc | Jakob Dupont | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2025 | 1,100 | 1,100 | - | - | Stock Option (Right to Buy) | |
| Bolt Biotherapeutics Inc | Jakob Dupont | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Pyxis Oncology Inc | Jakob Dupont | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 36,979 | 36,979 | - | - | Stock Option (Right to Buy) | |
| Bolt Biotherapeutics Inc | Jakob Dupont | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Bolt Biotherapeutics Inc | Jakob Dupont | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 16,984 | 16,984 | - | - | Stock Option (Right to Buy) | |
| Pyxis Oncology Inc | Jakob Dupont | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 38,741 | 38,741 | - | 0 | Common Stock | |
| Pyxis Oncology Inc | Jakob Dupont | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 17,250 | 17,250 | - | - | Stock Option (Right to buy) | |
| Pyxis Oncology Inc | Jakob Dupont | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 5,879 | 5,879 | - | - | Stock Option (Right to buy) | |
| Pyxis Oncology Inc | Jakob Dupont | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 3,534 | 3,534 | - | - | Stock Option (Right to buy) | |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 3.63 per share. | 02 Mar 2023 | 5,074 | 290,794 (0%) | 0% | 3.6 | 18,403 | Common Stock |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 317,987 | 317,987 | - | - | Employee Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 141,328 | 295,868 (0%) | 0% | 0 | Common Stock | |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 5.03 per share. | 16 Aug 2022 | 4,124 | 158,882 (0%) | 0% | 5.0 | 20,760 | Common Stock |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 5.32 per share. | 17 May 2022 | 3,873 | 163,006 (0%) | 0% | 5.3 | 20,597 | Common Stock |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 147,573 | 147,573 | - | - | Employee Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 78,506 | 169,100 (0%) | 0% | 0 | Common Stock | |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 9.86 per share. | 01 Mar 2022 | 2,221 | 166,879 (0%) | 0% | 9.9 | 21,890 | Common Stock |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.58 per share. | 10 Feb 2022 | 5,000 | 95,594 (0%) | 0% | 9.6 | 47,900 | Common Stock |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 5,000 | 257,500 | - | - | Employee Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 10 Feb 2022 | 5,000 | 90,594 (0%) | 0% | 16 | 80,000 | Common Stock |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 16.01 per share. | 03 Jan 2022 | 5,000 | 90,594 (0%) | 0% | 16.0 | 80,050 | Common Stock |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 5,000 | 262,500 | - | - | Employee Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.58 per share. | 03 Jan 2022 | 5,000 | 95,594 (0%) | 0% | 9.6 | 47,900 | Common Stock |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 17.12 per share. | 16 Nov 2021 | 2,199 | 90,594 (0%) | 0% | 17.1 | 37,640 | Common Stock |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 16.41 per share. | 02 Nov 2021 | 5,000 | 92,793 (0%) | 0% | 16.4 | 82,050 | Common Stock |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2021 | 5,000 | 272,500 | - | - | Employee Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.58 per share. | 02 Nov 2021 | 5,000 | 97,793 (0%) | 0% | 9.6 | 47,900 | Common Stock |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 12.53 per share. | 17 Aug 2021 | 2,152 | 92,793 (0%) | 0% | 12.5 | 26,969 | Common Stock |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 14.55 per share. | 18 May 2021 | 5,184 | 94,945 (0%) | 0% | 14.5 | 75,427 | Common Stock |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 81,327 | 81,327 | - | - | Employee Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Jakob Dupont | EVP, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 53,879 | 100,129 (0%) | 0% | 0 | Common Stock |